Canntab Therapeutics Limited

PILL

CA1377991023

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 14:07:30 2023-10-04 EDT			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-.--%

04-15	Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	CI
2023	Canntab Therapeutics Limited Provide an Update on Product Delivery	CI

Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2020

October 30, 2020 at 03:39 pm

Canntab Therapeutics Limited announced earnings results for the first quarter ended August 31, 2020. For the first quarter, the company announced operating loss was CAD 904,068 compared to CAD 443,831 a year ago. Net loss was CAD 900,992 compared to CAD 439,877 a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.02 a year ago.

Latest news about Canntab Therapeutics Limited

Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	04-14	CI
Canntab Therapeutics Limited Provide an Update on Product Delivery	23-08-22	CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-04-26	CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	23-01-26	CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022	22-10-27	CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt	22-09-27	CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022	22-09-27	CI
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market	22-08-22	MT
Canntab Therapeutics Limited Announces Chief Executive Office Changes	22-08-02	CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	22-04-29	CI
Canntab Therapeutics Limited Receives Approval from the Province of Saskatchewan to Begin Sales	22-03-23	CI
Canntab Therapeutics Limited Enters into Affiliate Agreement with Onpharm-United	22-03-23	CI
Canntab Therapeutics Limited Signs Historic Agreement with First Nations Growers Gp Inc. to Address the Opiate and Illicit Drug Crisis Affecting Indigenous Peoples Throughout Canada	22-02-07	CI
Canntab Therapeutics Limited announced that it has received CAD 1.312 million in funding	22-01-31	CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	22-01-31	CI
Canntab Therapeutics Limited Officially Launches its Online E-Commerce Platform	22-01-20	CI
Levitee Labs Inc. Enters into A Strategic Partnership Via A Services Agreement with Canntab Therapeutics Limited	22-01-10	CI
Canntab Delivers 1st Shipment to the Ontario Cannabis Store and 2nd Shipment to Australia	22-01-10	CI
Canntab Enters into Strategic Partnership to Provide Alternatives to Opiates Through Levitee Clinics	21-12-16	CI
Pathway Health Corp. Announces Agreement with Canntab Therapeutics Limited	21-12-02	CI
Canntab Therapeutics Limited Announces Agreement with Pathway Health	21-12-02	CI
Health Canada Awards Medical Sales Licence to Canntab	21-11-11	MT
Canntab Receives Medical Sales License from Health Canada	21-11-11	CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2021	21-11-01	CI
Canntab Reaches Agreement with 36eight Technologies Inc	21-10-18	CI

Chart Canntab Therapeutics Limited

Duration

Period

More charts

Company Profile

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Companyâs operations comprise a single segment engaged in the medical marijuana business. The Companyâs hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patientâs mouth, with an onset of action between five and thirty minutes.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
CANNTAB THERAPEUTICS LIMITED	-.--%	143K
DONG-E-E-JIAO CO.,LTD.	+39.90%	6.01B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-22.06%	4.11B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+10.94%	3.28B
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.63%	2.83B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-9.17%	2.31B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+44.13%	1.9B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-5.16%	1.55B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+52.16%	1.51B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-16.04%	1.49B